- Details
- Description
-
Packaging Size2vail/Box&4vail/Box
-
Strength2mg&4mg&6mg
-
CompositonMazdutide
-
TreatmentChronic Weight Management: Obesity and Overweight
-
FormInjection / Autoinjection Pen
-
Brand信尔美®
-
Quantity Unit2mg*2vail/Box&4mg*2vail/Box&6mg*2vail/Box
-
ManufacturerInnovent Biologics,china
About Mazdutide (IBI362)
Mazdutide , a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity.
- Mazdutide sold under the brand name 信尔美® in china.
<Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight>
Mazdutide is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:
- BMI ≥ 28 kg/m² (obesity); or
- BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome and etc.).
Mazdutide is injected once a week。
